目的:探讨腹膜透析治疗终末期肾病(ESRD)伴有慢性肝病患者的临床效果。方法:选取2014年8月至2019年5月河南宏力医院肾内科收治的30例ESRD伴有慢性肝病患者，男13例，女17例，年龄(49.33±11.06)岁，年龄范围为27～69岁，根据透析方式不同将其分为维持性血液透析(MHD)组(n n＝16)与持续非卧床腹膜透析(CAPD)组(n n＝14)。分别检测两组患者透析前后的各项指标，包括24 h尿量、肾小球滤过率、血尿素、血肌酐、血红蛋白、血钙、血磷、甲状旁腺素、血清白蛋白、C反应蛋白、碳酸氢盐及凝血酶时间并比较两组患者并发症，包括消化道出血、皮下出血、低血压、心力衰竭、腹膜炎的发生情况。n 结果:两组患者透析前各临床指标比较，差异均无统计学意义(n P>0.05)。透析6个月后CAPD组24 h尿量[(1 257.14±479.93)ml]、肾小球滤过率[(6.65±1.73)ml/min]、血红蛋白[(110.98±12.36)g/L]、血钙[(2.20±0.18)mmol/L]、碳酸氢盐[(25.34±2.63)mmol/L]均高于MHD组[(734.38±252.14)ml、(5.54±0.62)ml/min、(93.42±6.39)g/L、(1.96±0.16)mmol/L、(20.51±2.53)mmol/L]；血磷[(1.45±0.23)mmol/L]、甲状旁腺素[(232.26±106.93)pg/ml]、C反应蛋白[(0.66±0.47)mg/L]均显著低于MHD组[(1.80±0.40)mmol/L、(329.93±190.79)pg/ml、(4.08±1.88)mg/L]，差异均有统计学意义(n P0.05)。透析6个月后MHD组消化道出血8例，CAPD组2例；MHD组皮下出血9例，CAPD组0例；MHD组低血压9例，CAPD组1例，两组比较，差异均有统计学意义(n P0.05)。n 结论:腹膜透析治疗ESRD伴有慢性肝病患者效果好，并发症少，可作为此类患者优先考虑的透析方式。“,”Objective:To investigate the effect of peritoneal dialysis used for end-stage renal disease(ESRD)combined with chronic liver disease.Methods:A retrospective study was performed on 30 cases of patients with ESRD combined with chronic liver disease who were admitted to the department of Nephrology, Henan Honliv Hospital from August 2014 to May 2019.There were 13 males, 17 females, aged(49.33±11.06)years old, ranging from 27 to 69 years old.Patients were divided into the maintenance hemodialysis(MHD)group(n n=16)and continuous ambulatory peritoneal dialysis(CAPD)group(n n=14)according to different dialysis methods.The indexes before and after dialysis were detected, including 24 hours urine volume, glomerular filtration rate, blood urea, serum creatinine, hemoglobin, blood calcium, blood phosphorus, parathyroid hormone, serum albumin, C-reactive protein, bicarbonate and thrombin time were compared.The incidence of complications, including gastrointestinal bleeding, subcutaneous hemorrhage, hypotension, cardiac failure, peritonitis were compared between the two groups.n Results:Comparison of clinical indicators before dialysis between the two groups showed no statistically significant difference(n P>0.05). The 24 hours urine output in CAPD group after 6 months of dialysis[(1 257.14±479.93)ml], glomerular filtration rate[(6.65±1.73)ml/minutes], hemoglobin[(110.98±12.36)g/L], blood calcium[(2.20±0.18)mmol/L], and bicarbonate[(25.34±2.63)mmol/L] were all higher than MHD group[(734.38±252.14)ml, (5.54±0.62)ml/minutes, (93.42±6.39)g/L, (1.96±0.16)mmol/L, (20.51±2.53)mmol/L]; blood phosphorus[(1.45±0.23)mmol/L], parathyroid hormone[(232.26±106.93)pg/ml], and C-reactive protein[(0.66±0.47)mg/L] were significantly lower than MHD group[(1.80±0.40)mmol/L, (329.93±190.79)pg/ml and(4.08±1.88)mg/L], and the differences were statistically significant(n P0.05). After 6 months of dialysis, 8 patients in MHD group and 2 patients in CAPD group had gastrointestinal bleeding; 9 cases of subcutaneous hemorrhage in MHD group and 0 case in CAPD group; 9 cases of hypotension in MHD group and 1 case in CAPD group, and the differences were statistically significant(n P0.05).n Conclusion:Peritoneal dialysis in the treatment of ESRD combined with chronic liver disease has better effects, the complication is less, which should be the top-priority dialysis method for these patients.